Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 18/20 | 0.56 |
| ▸ | MTOR | P42345 | 2/20 | 0.56 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.56 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.56 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.56 |
| ▸ | METAP2 | P50579 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12676203 | 0.86 | PIK3CA (0.61) | PIK3CAMTORPIK3CDPIK3CBPIK3CG | |
| SCHEMBL13895692 | 0.84 | PIK3CA (0.59) | PIK3CAMTORPIK3CDPIK3CBPIK3CG | |
| SCHEMBL6128307 | 0.82 | PIK3CA (0.57) | PIK3CAMTORPIK3CDPIK3CBPIK3CG | |
| SCHEMBL1897638 | 0.80 | PIK3CA (0.55) | PIK3CAMTORPIK3CDPIK3CBPIK3CG | |
| SCHEMBL16144854 | 0.79 | PIK3CA (0.56) | PIK3CAMTORPIK3CDPIK3CBPIK3CG | |
| SCHEMBL1898411 | 0.78 | PIK3CA (0.60) | PIK3CAMTORPIK3CDPIK3CBPIK3CG | |
| SCHEMBL12457297 | 0.77 | PIK3CA (0.58) | PIK3CAMTORPIK3CDPIK3CBPIK3CG | |
| SCHEMBL1898472 | 0.75 | PIK3CA (0.65) | PIK3CAMTORPIK3CDPIK3CBPIK3CG | |
| SCHEMBL1897381 | 0.74 | PIK3CA (0.60) | PIK3CAMTORPIK3CDPIK3CBPIK3CG | |
| SCHEMBL1901238 | 0.74 | PIK3CA (0.60) | PIK3CAMTORPIK3CDPIK3CBPIK3CG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2322523-B1 | Process for the preparation of Pyridopyrimidinone Inhibitors of PI3Kalpha | EXELIXIS INC (US) | 2019-01-02 | — | — | EP | claimed |
| US-20140302012-A1 | Combination Therapies for Treating Hematologic Malignancies Using Pyridopyrimidinone Inhibitors of PI3K/mTOR with Bendamustine and/or Rituximab | SANOFI (FR) | 2014-10-09 | — | — | US | claimed |
| US-20140296265-A1 | Method of Treating Lymphoma Using Pyridopyrimidinone Inhibitors of PI3K/mTOR | SANOFI (FR) | 2014-10-02 | — | — | US | claimed |
| EP-1940839-B1 | PYRIDOPYRIMIDINONE INHIBITORS OF PI3Kalpha | EXELIXIS INC (US) | 2013-07-31 | — | — | EP | claimed |
| US-20130172371-A1 | Methods of Treating Cancer Using Pyridopyrimidinone Inhibitors of PI3K and mTOR in Combination with Autophagy Inhibitors | EXELIXIS, INC (US) | 2013-07-04 | — | — | US | claimed |
| US-8044062-B2 | Substituted pyrido[2,3-d]pyrimidin-7(8H)-one inhibitors of phospatidylinositol 3-kinase alpha | EXELIXIS, INC. (US) | 2011-10-25 | — | — | US | claimed |
| EP-2322523-A1 | Pyridopyrimidinone Inhibitors of PI3Kalpha | Exelixis, Inc. (US) | 2011-05-18 | — | — | EP | claimed |
| US-20090270430-A1 | Pyridopyrimidinone Inhibitors of Pl3Kalpha | EXELIXIX, INC. (US) | 2009-10-29 | — | — | US | claimed |
| EP-2322523-B1 | Process for the preparation of Pyridopyrimidinone Inhibitors of PI3Kalpha | EXELIXIS INC (US) | 2019-01-02 | — | — | EP | disclosed |
| EP-2322523-B1 | Process for the preparation of Pyridopyrimidinone Inhibitors of PI3Kalpha | EXELIXIS INC (US) | 2019-01-02 | — | — | EP | disclosed |
| US-8901137-B2 | Methods of treating cancer using pyridopyrimidinone inhibitors of PI3K and mTOR in combination with autophagy inhibitors | EXELIXIS, INC. (US) | 2014-12-02 | — | — | US | disclosed |
| US-8901137-B2 | Methods of treating cancer using pyridopyrimidinone inhibitors of PI3K and mTOR in combination with autophagy inhibitors | EXELIXIS, INC. (US) | 2014-12-02 | — | — | US | disclosed |
| US-8901137-B2 | Methods of treating cancer using pyridopyrimidinone inhibitors of PI3K and mTOR in combination with autophagy inhibitors | EXELIXIS, INC. (US) | 2014-12-02 | — | — | US | disclosed |
| US-20140302012-A1 | Combination Therapies for Treating Hematologic Malignancies Using Pyridopyrimidinone Inhibitors of PI3K/mTOR with Bendamustine and/or Rituximab | SANOFI (FR) | 2014-10-09 | — | — | US | disclosed |
| US-20100150827-A1 | PYRIDO [2, 3-D] PYRIMIDIN-7-ONE COMPOUNDS AS INHIBITORS OF P13K-ALPHA FOR THE TREATMENT OF CANCER | EXELIXIS, INC (US) | 2010-06-17 | — | — | US | disclosed |
| US-20090270430-A1 | Pyridopyrimidinone Inhibitors of Pl3Kalpha | EXELIXIX, INC. (US) | 2009-10-29 | — | — | US | disclosed |
| US-20090270430-A1 | Pyridopyrimidinone Inhibitors of Pl3Kalpha | EXELIXIX, INC. (US) | 2009-10-29 | — | — | US | disclosed |
| US-20090270430-A1 | Pyridopyrimidinone Inhibitors of Pl3Kalpha | EXELIXIX, INC. (US) | 2009-10-29 | — | — | US | disclosed |
| WO-2008124161-A1 | METHODS OF TREATING CANCER USING PYRIDOPYRIMIDINONE INHIBITORS OF PI3K ALPHA | EXELIXIS, INC. (US) | 2008-10-16 | — | — | WO | disclosed |
| WO-2007044813-A1 | PYRIDOPYRIMIDINONE INHIBITORS OF PI3Kα | EXELIXIS, INC. (US) | 2007-04-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090270430-A1 | Pyridopyrimidinone Inhibitors of Pl3Kalpha | PLK3, PLK4, PLK2 | PIK3CA 67/4885MTOR 2128/4885PIK3CD 75/4885 |
| US-20100150827-A1 | PYRIDO [2, 3-D] PYRIMIDIN-7-ONE COMPOUNDS AS INHIBITORS OF P13K-ALPHA FOR THE TREATMENT OF CANCER | PIK3CA, CDKN1A, PIK3CD | PIK3CA 1/4885MTOR 304/4885PIK3CD 3/4885 |
| US-20140302012-A1 | Combination Therapies for Treating Hematologic Malignancies Using Pyridopyrimidinone Inhibitors of PI3K/mTOR with Bendamustine and/or Rituximab | BTK, MTOR, BCL6 | PIK3CA 4/4885MTOR 2/4885PIK3CD 9/4885 |
| US-20140296265-A1 | Method of Treating Lymphoma Using Pyridopyrimidinone Inhibitors of PI3K/mTOR | MTOR, RICTOR, PIK3CA | PIK3CA 3/4885MTOR 1/4885PIK3CD 5/4885 |
| US-20130172371-A1 | Methods of Treating Cancer Using Pyridopyrimidinone Inhibitors of PI3K and mTOR in Combination with Autophagy Inhibitors | MTOR, PIK3CA, PIK3CD | PIK3CA 2/4885MTOR 1/4885PIK3CD 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.